Creative Planning Purchases 18,927 Shares of Immunomedics, Inc. (NASDAQ:IMMU)

Creative Planning grew its position in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 7.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 261,455 shares of the biopharmaceutical company’s stock after acquiring an additional 18,927 shares during the quarter. Creative Planning’s holdings in Immunomedics were worth $3,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mackay Shields LLC lifted its holdings in shares of Immunomedics by 1.9% during the 3rd quarter. Mackay Shields LLC now owns 139,696 shares of the biopharmaceutical company’s stock valued at $1,853,000 after buying an additional 2,600 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Immunomedics during the 3rd quarter valued at $1,132,000. Tocqueville Asset Management L.P. lifted its holdings in shares of Immunomedics by 42.9% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 51,300 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 15,400 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Immunomedics by 119.7% during the 3rd quarter. California Public Employees Retirement System now owns 291,800 shares of the biopharmaceutical company’s stock valued at $3,869,000 after buying an additional 159,000 shares during the period. Finally, Menora Mivtachim Holdings LTD. lifted its holdings in shares of Immunomedics by 181.4% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 1,434,900 shares of the biopharmaceutical company’s stock valued at $19,027,000 after buying an additional 925,000 shares during the period. 88.94% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Avoro Capital Advisors Llc acquired 1,000,000 shares of Immunomedics stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $13.23 per share, for a total transaction of $13,230,000.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Bryan Ball acquired 5,000 shares of Immunomedics stock in a transaction dated Thursday, October 3rd. The stock was bought at an average price of $14.18 per share, with a total value of $70,900.00. Following the completion of the purchase, the insider now directly owns 10,000 shares in the company, valued at $141,800. The disclosure for this purchase can be found here. Corporate insiders own 9.40% of the company’s stock.

NASDAQ:IMMU opened at $17.46 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a market capitalization of $3.43 billion, a price-to-earnings ratio of -16.95 and a beta of 2.13. Immunomedics, Inc. has a one year low of $11.55 and a one year high of $23.08. The business has a fifty day moving average price of $15.47 and a 200-day moving average price of $14.67.

Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.09). During the same period in the previous year, the firm posted ($0.34) earnings per share. On average, equities research analysts expect that Immunomedics, Inc. will post -1.78 earnings per share for the current fiscal year.

Several research firms have recently weighed in on IMMU. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Immunomedics in a report on Thursday, October 31st. Cowen set a $30.00 price target on Immunomedics and gave the company a “buy” rating in a report on Sunday, September 29th. Jefferies Financial Group set a $22.00 price target on Immunomedics and gave the company a “buy” rating in a report on Tuesday, September 10th. Cantor Fitzgerald began coverage on Immunomedics in a report on Monday, August 19th. They set an “overweight” rating and a $28.00 price target on the stock. Finally, B. Riley set a $28.00 price target on Immunomedics and gave the company a “buy” rating in a report on Monday, September 30th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $26.22.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Read More: How To Calculate Debt-to-Equity Ratio

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.